VeinWay News
8 articles
growth-positive
VeinWay CEO: “This is a pivotal year for us” - Venous News
VeinWay, a medical device company specializing in venous disease, is planning to start a 30-patient trial to support FDA clearance and initial commercialization efforts by the end of 2024. The company has already successfully performed seven compassionate-use cases with its Traversa device, a tool for crossing tough venous occlusions. CEO Jordan Pollack anticipates challenges in fundraising but also sees a lot of interest from major strategic players. He envisions VeinWay becoming a prominent company in the venous space, filling a gap left by larger companies focusing on arterial disease.
InvestmentExpand
Growth-Positive
VeinWay Closes Oversubscribed SAFE Round and Begins Series A Round
VeinWay, a medical device company, has successfully closed an oversubscribed SAFE round of investment and has opened a series A round. The funds will be used to complete design verification testing and to prepare for VeinWay’s First-in-Human clinical trial of its Traversa system towards an FDA IDE trial planned for the first half of 2024. The company also announced that Stephen Black, MD and Houman Jalaie, MD, PhD have joined the company’s scientific advisory board.
InvestmentManagement Changes
growth-positive
VeinWay opens up the path to stop blood clots in underappreciated patients | CTech
VeinWay Ltd., a company focused on improving access to healthcare for patients with chronic venous disease, has raised $2.5 million in its latest investment round. The company is developing a novel catheter called Traversa, which is designed to safely and efficiently cross chronic blockages in veins. The Traversa device aims to significantly shorten procedure time and improve outcomes for patients. VeinWays CEO, Jordan Pollack, and CTO, Ben Friesem, bring extensive experience in medical device design and engineering to the company. The market for venous chronic total occlusion (CTO) devices is emerging, and VeinWay aims to jumpstart the market with its dedicated crossing tool. The companys main customers are interventional radiologists and vascular surgeons. Traversa has been used in clinical cases and will undergo a formal clinical trial starting in October 2023. VeinWay plans to seek FDA and EU MDR approval in late 2024 and 2025, respectively.
Investment
growth-positive
Health Tech: Jordan Pollack on How VeinWay's Technology Can Make an Important Impact on Our Overall...
The article is an interview with Jordan Pollack, the CEO of VeinWay, a medical technology company that is part of the MEDX Xelerator portfolio. Pollack discusses his career journey, the challenges he faced, and the inspiration behind VeinWay. The company is developing a device to treat Chronic Venous Occlusions (CVOs), a condition that affects almost 20% of people worldwide. The device, called Traversa, is designed to recanalize chronic venous occlusions quickly, safely, and efficiently. Pollack believes that the device will democratize chronic DVT/PTS treatment and improve the quality of life for patients.
Management ChangesExpand
growth-positive
MEDX Xelerator Invests In Three New Health Technology Ventures
MEDX Xelerator has founded three new start-up companies as part of its technology development program. The companies will receive financing and support services to expedite their technology development. The three companies are VeinWay, EyeMed, and BeWeld, which focus on treating chronic venous blockages, premium lenses for intraocular implantation, and automating the manufacturing processes of implantable devices, respectively. MEDX Xelerator collaborates with hospitals and multinational companies to identify and address unmet clinical needs through innovation. The incubator has achieved significant milestones, including collaborations with CBG and West Pharmaceutical Services, and the establishment of a program for cardiovascular medical device entrepreneurs seeking financing. MEDX Xelerator is a leading international medical device and digital health-focused incubator founded in 2016 and operates under the Israel Innovation Authority.
PartnersInvestment
growth-positive
https://www.jpost.com/israel-news/from-minnesota-to-tel-aviv-oleh-finds-israelis-welcoming-and-warm-659386
The article discusses the journey of Jordan Pollack, a biomedical engineer who moved from Chicago to Tel Aviv to start his own company called VeinWay. VeinWay is a member of MEDX Xelerators X Lab program and recently received a $35,000 grant from Tnufa - The Ideation Incentive Program of the Israel Innovation Authority. Pollack praises the Israeli start-up ecosystem for being more welcoming of entrepreneurs and tolerant of mistakes and failures compared to the US. However, he also mentions the bureaucracy and slow government processes in Israel. He is determined to learn Hebrew and integrate into the Israeli culture. Pollacks family is proud of his decision to move to Israel and pursue his dreams.
Investment
MEDX Xelerator Approves New "X Lab" Project to Improve Treatment of Peripheral Venous Disease Care, Forms VeinWay Under CEO Jordan Pollack
growth-positive
MEDX Xelerator Approves New "X Lab" Project to Improve Treatment of Peripheral Venous Disease Care, Forms VeinWay Under CEO Jordan Pollack
VeinWay, a newly formed company focused on treating peripheral venous disease, has received a grant of over $35K from The Ideation (Tnufa) Incentive Program of The Israel Innovation Authority. The grant aims to support the company in reaching proof of concept and business feasibility. VeinWay is headed by Jordan Pollack, an experienced biomedical engineer and entrepreneur. The company is part of MEDX Xelerators X Lab program, which helps inventors and entrepreneurs develop their ideas. If a proof of concept is demonstrated, VeinWay may enter the formal incubator program. The goal is to improve care for patients with peripheral venous disease.
Investment